Sensory neuron–expressed FGF13 controls nociceptive signaling in diabetic neuropathy models
Journal of Clinical Investigation · 2025
DOI: 10.1172/jci183749 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Aditya K Singh und 49 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, The University of Texas Medical Branch, Galveston, Texas, USA. Hauptthemen laut MEDLINE: Fibroblast Growth Factors, Sensory Receptor Cells, Diabetic Neuropathies, NAV1.7 Voltage-Gated Sodium Channel. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIMH NIH HHS, NINDS NIH HHS, NIA NIH HHS.
Abstract (Originalsprache)
Nociception involves complex signaling, yet intrinsic mechanisms bidirectionally regulating this process remain unexplored. Here, we show that the fibroblast growth factor 13 (FGF13)/Nav1.7 protein–protein interaction (PPI) complex bidirectionally modulates nociception, and that the FGF13/Nav1.7 ratio is upregulated in type 2 diabetic neuropathy (T2DN). PW164, an FGF13/Nav1.7 channel C-terminal tail domain (CTD) PPI interface inhibitor, which reduces complex assembly, selectively suppressed Na + currents sensitized by capsaicin-induced activation of TRPV1 channels in human induced pluripotent stem cell–derived (hIPSC-derived) sensory neurons and inhibited mechanical and thermal hyperalgesia in mice. FGF13 silencing mimics PW164 activity in culture and in vivo. Conversely, ZL192, an FGF13 ligand that stabilizes FGF13/Nav1.7 CTD assembly, sensitized Na + currents in hIPSC-derived sensory neurons and exerted pronociceptive behavioral responses in mice. ZL192’s effects were abrogated by FGF13 silencing in culture and in vivo and recapitulated by FGF13 overexpression. In a model of T2DN, PW164 injection reduced mechanical hyperalgesia locally and contralaterally without systemic side effects. In donor-derived dorsal root ganglia neurons, FGF13 and Nav1.7 proteins colocalized, and the FGF13/Nav1.7 protein ratio was upregulated in patients with T2DN. Lastly, we found that SCN9A variant V1831F, associated with painless diabetic neuropathy, abolished PW164-directed modulation of the FGF13/Nav1.7 PPI interface. Thus, FGF13 is a rheostat of nociception and promising therapeutic target for diabetic neuropathy pain.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, The University of Texas Medical Branch, Galveston, Texas, USA.
- Department of Anesthesiology, University of Cincinnati, College of Medicine, Cincinnati, Ohio, USA.
- Department of Neurobiology and.
- Department of Orthopaedic Surgery and Rehabilitation, The University of Texas Medical Branch, Galveston, Texas, USA.
- Anatomic Incorporated, Minneapolis, Minnesota, USA.
- Department of Neuroscience, Center for Advanced Pain Studies, The University of Texas at Dallas, Dallas, Texas, USA.
Förderung
- NIMH NIH HHS
- NINDS NIH HHS
- NIA NIH HHS
- NIEHS NIH HHS
- NIDA NIH HHS
- NIH HHS
- NIGMS NIH HHS
- National Institute of Mental Health
Zitieren
APA
Singh, A. K., Bernabucci, M., Dvorak, N. M., Haghighijoo, Z., Di Re, J., Goode, N. A., Kadakia, F. K., Maile, L. A., Folorunso, O. O., Wadsworth, P. A., Tapia, C. M., Wang, P., Wang, J., Chen, H., Xue, Y., Singh, J., Hankerd, K., Gamez, I. J., Kager, M., …, & Laezza, F. (2025). Sensory neuron–expressed FGF13 controls nociceptive signaling in diabetic neuropathy models. Journal of Clinical Investigation. https://doi.org/10.1172/jci183749
Vancouver
Singh AK, Bernabucci M, Dvorak NM, Haghighijoo Z, Di Re J, Goode NA, et al. Sensory neuron–expressed FGF13 controls nociceptive signaling in diabetic neuropathy models. Journal of Clinical Investigation. 2025. doi:10.1172/jci183749
BibTeX
@article{Singh2025,
author = {Singh, Aditya K and Bernabucci, Matteo and Dvorak, Nolan M and Haghighijoo, Zahra and Di Re, Jessica and Goode, Nana A and Kadakia, Feni K and Maile, Laura A and Folorunso, Olumarotimi O and Wadsworth, Paul A and Tapia, Cynthia M and Wang, Pingyuan and Wang, Jigong and Chen, Haiying and Xue, Yu and Singh, Jully and Hankerd, Kali and Gamez, Isaac J and Kager, Makenna and Truong, Vincent and Walsh, Patrick and Shiers, Stephanie I and Kuttanna, Nishka and Liao, Hanyue and Marchi, Margherita and Salvi, Erika and D'Amato, Ilaria and D'Amico, Daniela and Arman, Parsa and Faber, Catharina G and Malik, Rayaz A and de Tommaso, Marina and Ziegler, Dan and Rajarathnam, Krishna and Green, Thomas A and Grace, Peter M and Sapio, Matthew R and Iadarola, Michael J and Cuny, Gregory D and Chow, Diana S and Lauria Pinter, Giuseppe and Davidson, Steve and Green, Dustin P and La, Jun-Ho and Chung, Jin Mo and Zhou, Jia and Price, Theodore J and Salisbury, Elizabeth and Yuan, Subo and Laezza, Fernanda},
title = {Sensory neuron–expressed FGF13 controls nociceptive signaling in diabetic neuropathy models},
journal = {Journal of Clinical Investigation},
year = {2025},
doi = {10.1172/jci183749}
}
EUVIMED